Ontology type: schema:ScholarlyArticle
2011-10-06
AUTHORSG. Bianchi, E. Czerwinski, A. Kenwright, A. Burdeska, R. R. Recker, D. Felsenberg
ABSTRACTLong-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis.IntroductionTreatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-term extension (LTE) to the 2-year DIVA trial.MethodsDIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≥75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate.ResultsPooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXA-BMD (8.4% [95% confidence interval (CI) = 7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI = 7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed.ConclusionsTreatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis. More... »
PAGES1769-1778
http://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9
DOIhttp://dx.doi.org/10.1007/s00198-011-1793-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1038256783
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/21975558
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Absorptiometry, Photon",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Administration, Oral",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biomarkers",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density Conservation Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Diphosphonates",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ibandronic Acid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infusions, Intravenous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Longitudinal Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lumbar Vertebrae",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Osteoporosis, Postmenopausal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Rheumatology, Azienda Sanitaria Genovese, Genoa, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Division of Rheumatology, Azienda Sanitaria Genovese, Genoa, Italy"
],
"type": "Organization"
},
"familyName": "Bianchi",
"givenName": "G.",
"id": "sg:person.0607571556.89",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607571556.89"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Krakow Medical Centre, Krakow, Poland",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Krakow Medical Centre, Krakow, Poland"
],
"type": "Organization"
},
"familyName": "Czerwinski",
"givenName": "E.",
"id": "sg:person.0637750557.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637750557.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Roche Products Limited, Welwyn Garden City, UK",
"id": "http://www.grid.ac/institutes/grid.419227.b",
"name": [
"Roche Products Limited, Welwyn Garden City, UK"
],
"type": "Organization"
},
"familyName": "Kenwright",
"givenName": "A.",
"id": "sg:person.0654675727.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654675727.29"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "F. Hoffmann-La Roche Ltd., Basel, Switzerland",
"id": "http://www.grid.ac/institutes/grid.417570.0",
"name": [
"F. Hoffmann-La Roche Ltd., Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Burdeska",
"givenName": "A.",
"id": "sg:person.013722740000.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722740000.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Osteoporosis Research Center, Creighton University, Omaha, NE, USA",
"id": "http://www.grid.ac/institutes/grid.254748.8",
"name": [
"Osteoporosis Research Center, Creighton University, Omaha, NE, USA"
],
"type": "Organization"
},
"familyName": "Recker",
"givenName": "R. R.",
"id": "sg:person.016325222544.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Charit\u00e9\u2014Campus Benjamin Franklin, Freie and Humboldt-Universit\u00e4t Berlin, Berlin, Germany",
"id": "http://www.grid.ac/institutes/grid.6363.0",
"name": [
"Charit\u00e9\u2014Campus Benjamin Franklin, Freie and Humboldt-Universit\u00e4t Berlin, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "Felsenberg",
"givenName": "D.",
"id": "sg:person.01210634005.52",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210634005.52"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00198-006-0322-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012288373",
"https://doi.org/10.1007/s00198-006-0322-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11914-009-0003-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015034231",
"https://doi.org/10.1007/s11914-009-0003-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf03346353",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022747871",
"https://doi.org/10.1007/bf03346353"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00002018-200932090-00002",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051242423",
"https://doi.org/10.2165/00002018-200932090-00002"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-003-1435-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052883806",
"https://doi.org/10.1007/s00198-003-1435-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00003495-200666120-00005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1010970356",
"https://doi.org/10.2165/00003495-200666120-00005"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-008-0653-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052235097",
"https://doi.org/10.1007/s00198-008-0653-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.14310/horm.2002.1226",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1067262245",
"https://doi.org/10.14310/horm.2002.1226"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-011-1549-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040089691",
"https://doi.org/10.1007/s00198-011-1549-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00002018-200730090-00003",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052609562",
"https://doi.org/10.2165/00002018-200730090-00003"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-004-0286-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007415759",
"https://doi.org/10.1007/s00223-004-0286-7"
],
"type": "CreativeWork"
}
],
"datePublished": "2011-10-06",
"datePublishedReg": "2011-10-06",
"description": "Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3\u00a0mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5\u00a0years (8.1%) and was well tolerated in women with postmenopausal osteoporosis.IntroductionTreatment with IV ibandronate regimens, 2\u00a0mg bimonthly and 3\u00a0mg quarterly, has been studied for up to 5\u00a0years in a long-term extension (LTE) to the 2-year DIVA trial.MethodsDIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2\u00a0years of DIVA core, comparing daily oral and IV ibandronate (\u226575% adherence with IV ibandronate in year\u00a02 of DIVA). Patients previously treated with 2\u00a0mg bimonthly or 3\u00a0mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5\u00a0mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate.ResultsPooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5\u00a0years in lumbar spine DXA-BMD (8.4% [95% confidence interval (CI)\u2009=\u20097.5, 9.3] with 2\u00a0mg bimonthly and 8.1% [95% CI\u2009=\u20097.2, 8.9] with 3\u00a0mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed.ConclusionsTreatment with IV ibandronate 2\u00a0mg bimonthly or 3\u00a0mg quarterly is effective and well tolerated for up to 5\u00a0years in women with postmenopausal osteoporosis.",
"genre": "article",
"id": "sg:pub.10.1007/s00198-011-1793-9",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1100834",
"issn": [
"0937-941X",
"1433-2965"
],
"name": "Osteoporosis International",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "23"
}
],
"keywords": [
"long-term extension",
"postmenopausal osteoporosis",
"lumbar spine bone mineral density",
"DXA-BMD",
"bone mineral density gains",
"spine bone mineral density",
"dual-energy X-ray absorptiometry",
"quarterly intravenous ibandronate",
"daily oral ibandronate",
"full ITT population",
"open-label extension",
"bone marker levels",
"new safety signals",
"long-term administration",
"bone mineral density",
"X-ray absorptiometry",
"intravenous ibandronate",
"ibandronate regimens",
"oral ibandronate",
"placebo IV",
"ITT population",
"postmenopausal women",
"same regimen",
"treat patients",
"tolerability concerns",
"marker levels",
"administration trial",
"bone metabolism",
"mineral density",
"safety signals",
"ibandronate",
"sustained reduction",
"patients",
"osteoporosis",
"women",
"trials",
"baseline",
"dive trials",
"core baseline",
"years",
"consistent increase",
"regimens",
"regimen",
"IntroductionTreatment",
"noninferiority",
"ConclusionsTreatment",
"absorptiometry",
"administration",
"three-year data",
"markers",
"metabolism",
"safety",
"population",
"further gains",
"levels",
"data",
"gain",
"density gain",
"study",
"benefits",
"intent",
"increase",
"reduction",
"maintenance",
"concern",
"analysis",
"extension",
"signals",
"density",
"core"
],
"name": "Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension",
"pagination": "1769-1778",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1038256783"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00198-011-1793-9"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"21975558"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00198-011-1793-9",
"https://app.dimensions.ai/details/publication/pub.1038256783"
],
"sdDataset": "articles",
"sdDatePublished": "2022-09-02T15:54",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_533.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00198-011-1793-9"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'
This table displays all metadata directly associated to this object as RDF triples.
300 TRIPLES
21 PREDICATES
125 URIs
106 LITERALS
26 BLANK NODES